Buy Regenovue Fine Plus Lidocaine Online
Regenovue Fine Plus Lidocaine containing 24mg HA can be used for periorbital lines, glabellar linesand neck folds lasting 8-12 months.
High Quality Hyaluronic Acid
Non animal base
Bacterial extract natural substance
High Purity(Endotoxin ＜0.0015IU/mg)
Biodegradable
Highly Crossed-Linked
Linking material: BDDE
Specialized manufacturing technique: Patent pending
Increasing volume and duration
High Viscosity
Long-lasting duration
Supports skin texture stably to maintain elasticity
Highly Consistent Monophasic Structure
Regular and compact pattern
Stable and constant structure
Natural volume
Smooth injecting feeling
Having Full Line-Up
Various choice and accurate application
Including Lidocaine
The Benefits of Lidocaine
One of the standout features of Regenovue Fine Plus is the addition of lidocaine, a local anesthetic. Lidocaine serves to minimize discomfort during the injection process, enhancing patient comfort and overall satisfaction. By reducing pain perception, lidocaine allows for a smoother and more pleasant treatment experience, encouraging patients to undergo subsequent sessions without hesitation.
Safety and Longevity
Regenovue Fine Plus Lidocaine is manufactured using advanced cross-linking technology, ensuring optimal stability and longevity of results. Additionally, being composed of biocompatible materials, such as hyaluronic acid, the risk of adverse reactions is minimal. Patients can expect to enjoy the benefits of their treatment for up to several months before considering a touch-up session.
Conclusion
In the pursuit of youthful, radiant skin, Regenovue Fine Plus emerges as a frontrunner in the realm of dermal fillers. With its innovative formulation, targeted approach, and emphasis on patient comfort, it represents a significant advancement in aesthetic medicine. As always, it is essential to consult with a qualified and experienced practitioner to determine the most suitable treatment plan based on individual needs and goals.
Reviews
There are no reviews yet.